Imperial Tobacco Canada: Ban on ZONNIC Nicotine Pouches in Convenience Stores Leads to Cigarette Sales Rebound, Calls for Restoring Multi-Channel Supply

Aug.20.2025
Imperial Tobacco Canada: Ban on ZONNIC Nicotine Pouches in Convenience Stores Leads to Cigarette Sales Rebound, Calls for Restoring Multi-Channel Supply
Imperial Tobacco Canada stated that one year ago, the government removed the nicotine pouch ZONNIC from convenience stores, restricting sales to behind-the-counter in pharmacies. This move caused ZONNIC sales to plummet, cigarette sales to rebound by 2.8%, and was accompanied by a surge of high-dose illegal nicotine pouches and black-market cigarettes (exceeding 500 million packs annually). The company is calling for an evidence-based harm reduction approach to restore multi-channel supply throu

Key Points:

  • Opposite policy effect: After ZONNIC was banned from convenience stores, legal product sales plummeted, while cigarette consumption increased.
  • Black market surge: Illegal nicotine pouches quickly flooded the market, with nicotine levels far above legal limits, easily accessible to both youth and adults.
  • Setback for quitters: In rural and remote areas lacking pharmacy access, adult smokers faced greater obstacles.
  • Pharmacist burden: Significant increase in administrative workload, diverting resources from patient care.
  • Economic blow: Affecting about 200,000 convenience retail jobs nationwide, threatening small businesses that rely on legal nicotine product sales.

 


 

According to Newswire on August 19, Imperial Tobacco Canada announced that one year ago, the Canadian government prohibited the sale of ZONNIC — the only nicotine pouch approved by Health Canada as a smoking cessation product — in convenience stores, allowing sales only behind pharmacy counters. The policy was intended to control nicotine product use and protect public health. However, new data show the measure has had the exact opposite effect.

 

Illegal sales surge: Many unregulated nicotine pouches with nicotine contents far above legal limits are now flooding both the physical market and e-commerce platforms, easily accessible to both youths and adults.

 

Smokers face barriers to quitting: In rural and remote areas where pharmacies are scarce, adult smokers who relied on ZONNIC to quit are now facing unnecessary obstacles.

 

Pharmacists under pressure: Pharmacists play an indispensable role in smoking cessation, but instead of focusing their time on essential patient care, they are now burdened with additional and unnecessary administrative work.

 


 

Over the past year, ZONNIC sales plummeted while cigarette sales increased by 2.8%. At the same time, the illicit market rapidly expanded, with more than 500 million unregulated nicotine pouches entering the market, many containing nicotine far above legal limits, and sold through retailers and online platforms — making them easily available to young people.

 

Eric Gagnon, Vice President of Corporate and Regulatory Affairs at Imperial Tobacco Canada, criticized the policy:

 

“The government cracked down on the country’s only legal, regulated nicotine pouch, but fueled the black market. ZONNIC was never the problem — it was the solution for many smokers.”

 


 

In addition to the rising risks of illegal products, smokers attempting to quit are also heavily impacted. In remote regions with limited pharmacy access, many adults have lost convenient access to ZONNIC. Pharmacists, meanwhile, are burdened with additional administrative tasks, diverting resources away from patient care.

 

On the economic front, the policy has hit the convenience retail sector hard, threatening about 200,000 related jobs nationwide and leaving small businesses dependent on legal nicotine product sales struggling to survive.

 


 

Previously, ZONNIC had been approved by Health Canada as a natural health product and smoking cessation aid, and was endorsed by the Centre for Addiction and Mental Health (CAMH) in Toronto. Data showed that in convenience stores selling ZONNIC, cigarette sales saw double-digit declines, demonstrating its positive effect in helping smokers quit.

 

Imperial Tobacco Canada reiterated its support for the federal government’s goal of reducing the smoking rate to below 5% by 2035, but stressed that this can only be achieved through wider access to innovative cessation tools.

 

Gagnon emphasized:

 

“We are willing to work with Health Canada to ease the burden on pharmacists and help more adults quit smoking for good.”

 

The company urged Canada to adopt evidence-based public health policies to ensure that cessation tools remain conveniently accessible, rather than making the path to quitting smoking more difficult.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Holdings said the U.S. Food and Drug Administration notified the company on June 23, 2026, that 30 PACHA vape SKUs with submitted PMTAs had been tentatively identified for inclusion on a planned public-facing FDA webpage. Under enforcement guidance issued by FDA in May, the webpage is intended to identify certain unauthorized products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements. Charlie’s disclosed the development alongside second-quarter revenue of $3.8 million, up 116% year over year.
Aug.25
DOJ Trade Fraud Task Force Tops $1 Billion in Cases, Putting Vape Supply Chains at Risk of Fraud Enforcement
DOJ Trade Fraud Task Force Tops $1 Billion in Cases, Putting Vape Supply Chains at Risk of Fraud Enforcement
According to the U.S. Department of Justice (DOJ), Fox News and other reports, the DOJ’s Trade Fraud Task Force (TFTF) has been linked to more than $1 billion in recoveries, penalties, forfeitures and publicly charged losses in less than one year. The task force focuses on trade fraud issues including country-of-origin fraud, illegal transshipment, false declarations and tariff evasion. While vape products are not the main source of the $1 billion figure, the industry’s reliance on global manufacturing and cross-border supply chains places it within broader U.S. trade enforcement scrutiny. The development suggests that U.S. oversight of cross-border vape products may increasingly extend beyond product authorization into import compliance, supply-chain transparency and corporate accountability.
Jul.23
Product | Republic Technologies Launches ZIG Nicotine Pouches, Expanding Beyond Traditional Tobacco Accessories
Product | Republic Technologies Launches ZIG Nicotine Pouches, Expanding Beyond Traditional Tobacco Accessories
Republic Technologies UK has entered the nicotine pouch market with ZIG Nicotine Pouches, marking the company’s expansion beyond traditional tobacco-related accessories into smoke-free nicotine products. The product is expected to enter UK retail channels from August 2026, including convenience stores, supermarkets and tobacco retailers. The launch includes six flavors and three nicotine strengths: 8mg, 12mg and 17mg.
Market
Jul.21 by 2Firsts Perspectives
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
PMI Q2 Revenue Rises 10.4% as IQOS and VEEV Expand, U.S. ZYN Growth Slows
PMI Q2 Revenue Rises 10.4% as IQOS and VEEV Expand, U.S. ZYN Growth Slows
Philip Morris International’s second-quarter net revenues rose 10.4% to a record $11.19 billion, as heated tobacco and e-vapor expanded across international markets. IQOS remained the main smoke-free growth engine, while VEEV shipments jumped 55.1%. In the United States, however, ZYN shipments increased just 1.8% and consumer offtake was broadly flat to slightly higher. Cigarette volumes also rose, showing that PMI’s transformation is advancing, but growth is becoming increasingly uneven across categories and markets.
PMI
Jul.22
Product | VEEV One Plus Goes Official as PMI Strengthens Its Closed-Pod Vaping Portfolio
Product | VEEV One Plus Goes Official as PMI Strengthens Its Closed-Pod Vaping Portfolio
Philip Morris International (PMI) has officially introduced the VEEV One Plus, the next-generation device in its closed-pod vaping lineup. The product is now featured on the official VEEV website in Portugal, bringing hardware upgrades including a new dual-pod storage system, a larger battery, and an updated device design while maintaining compatibility with existing VEEV One pods.
Jul.02